

**In the Claims**

Please amend the claims as follows. Applicant presents a full set of claims showing markups of the claims with insertions and deletions indicated by underlining (or double bracketing) and strikethrough text, respectively.

1. (Currently amended) A method for delivering an anti-target compound to a subject for the treatment of a disorder without being inactivated by orally administering thereto a polypeptide construct comprising one or more single domain antibodies directed against said target.
2. (Currently amended) A method according to claim 1 wherein said target is located in the gut system, ~~and said polypeptide construct is delivered orally.~~
- 3.-4. (Canceled)
5. (Currently amended) A method according to claim 1 wherein said target is located in intestinal mucosa, ~~and said polypeptide construct is delivered orally.~~
- 6.-7. (Canceled)
8. (Currently amended) A method according to claim 1 wherein said target is in, or accessible via the blood, ~~and said polypeptide construct is delivered orally, to the vaginal and/or rectal tract, nasally, by inhalation through the mouth or nose, to the tissues beneath the tongue, or topically.~~
- 9.-14. (Canceled)
15. (Previously presented) A method according to claim 1, wherein said target is TNF-alpha and the disorder is inflammation.

16. (Previously presented) A method according to claim 15, wherein the single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 12 to 14.
17. (Previously presented) A method according to claim 1, wherein said target is CEA and the disorder is colon cancer.
18. (Previously presented) A method according to claim 1, wherein said target is EGFR and the disorder is any of head, neck, lung and colon cancer.
19. (Previously presented) A method according to claim 18, wherein the single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 23 to 44.
20. (Currently amended) A method according to claim 1, wherein said target is an antigen of *Helicobacter pylori* and the disorder is any of indigestion and gastritis.
21. (Currently amended) A method according to claim 1, wherein said target is an antigen of *Mycobacterium tuberculosis* and the disorder is tuberculosis.
22. (Currently amended) A method according to claim 1, wherein said target is an antigen of *influenza* virus and the disorder is flu.
23. (Currently amended) A method according to claim 1, wherein said target is an antigen of MMP and the disorder is cancer.
24. (Previously presented) A method according to claim 23, wherein the single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 15 to 22.
25. (Previously presented) A method according to claim 1, wherein said target is an antigen of IFN-gamma and the disorder is any of cancer, transplant rejection, auto immune disorder.

26. (Previously presented) A method according to claim 25, wherein the single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 45 to 70.

27. (Previously presented) A method according to claim 1, wherein said target is any of an antigen of *Helicobacter pylori*, an antigen of *Mycobacterium tuberculosis*, and an antigen of influenza virus.

28.-45. (Canceled)

46. (Currently amended) A ~~polypeptide construct according to any of claims 9 or 28, or as used in a~~ method according to claim 1, wherein the single domain antibodies are humanized *Camelidae* VHHs, an homologous sequence, a functional portion, or a functional portion of an homologous sequence of the full length single domain antibody, or wherein the polypeptide construct is an homologous sequence, a functional portion, or a functional portion of an homologous sequence of the full length polypeptide construct.

47.-51. (Canceled)

52. (Currently amended) A method according to claim 1, wherein said target is an antigen of IgE and the disorder is an allergic response or a disorder relating to inflammatory processes.

53. (Previously presented) A method according to claim 52, wherein a single domain antibody corresponds to a sequence represented by any of SEQ ID NOs: 1 to 11.

54.-63. (Canceled)

64. (New) A method according to claim 2, wherein said target is located in the stomach or colon.

65. (New) A method for delivering an anti-target compound to the gut system without being inactivated, by orally administering to a subject a polypeptide construct comprising one or more single domain antibodies directed against said target.
66. (New) A method for delivering an anti-target compound to the intestinal mucosa without being inactivated, by orally administering to a subject a polypeptide construct comprising one or more single domain antibodies directed against said target.
67. (New) A method for delivering an anti-target compound to the bloodstream of a subject without being inactivated, by orally administering to a subject a polypeptide construct comprising one or more single domain antibodies directed against said target.